Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its wholly-owned medical devices subsidiary, Designer Diagnostics, has started marketing the first-ever environmental test kit for the detection of Nontuberculous Mycobacteria (NTM) in water and soil.
“The primary goal of these environmental test kits is to reduce the number of NTM infections worldwide by preventing the public’s exposure to NTM and determining the source of origin of NTM infections in patients,” explained Neil Roth, President of Designer Diagnostics. “In order to accomplish this goal, we believe that every municipality, hospital and water treatment facility should have these test kits on hand for periodic testing of the environment,” he added.
Nontuberculous Mycobacterium, also known as atypical Tuberculosis (Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a bacteria that is found in a multitude of environments --- in the soil, in some domestic and wild animals, and perhaps most importantly, in water, including showers and hot tubs. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex (MAC). This is a primary cause of respiratory disease in humans and is a leading cause of death in HIV/AIDS patients.
In December, Nutra Pharma announced that it expanded its licensing agreement with Ohio-based NanoLogix, Inc. to include additional intellectual property for the use of testing the environment for NTM.
“All of us at NanoLogix are excited that this beneficial technology is finally coming to market,” said Bret Barnhizer, CEO of NanoLogix, Inc. “These test kits will not only play an important role in reducing NTM infections in developing nations, but will also assist in the detection and prevention of NTM exposure and infection in the United States and other developed countries,” he added.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The marketing of Designer Diagnostics’ environmental test kits should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.